Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non Interventional Post Authorisation Multicenter Study to Evaluate the Disease Control (Benign Prostate Hyperplasia Control) and Quality of Life (QoL) Following the 6-months Combination Treatment With Dutasteride and Tamsulosin. PROSPERITY Group of Studies (I&II).

NCT04831476 is registered in ClinicalTrials.gov with Elpen Pharmaceutical Co. Inc. as lead sponsor.

NCT NCT04831476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04831476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non Interventional Post Authorisation Multicenter Study to Evaluate the Disease Control (Benign Prostate Hyperplasia Control) and Quality of Life (QoL) Following the 6-months Combination Treatment With Dutasteride and Tamsulosin. PROSPERITY Group of Studies (I&II).
Lead sponsor
Elpen Pharmaceutical Co. Inc.
Phase
Observational
Overall status
Completed
Start date
September 1, 2021
Completion date
October 31, 2022
Enrollment
1,296 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia